Skip to main content
logo
Citius Oncology, Inc. (CTOR)
NASDAQ: CTOR · Real-Time Price · USD
0.7756
-0.0147 (-1.86%)
At close: Aug 28, 2026, 4:00 PM EDT
0.7800
+0.0044 (0.57%)
After-hours: Aug 28, 2026, 6:27 PM EDT

Company Description

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies.

It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma.

The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.

Citius Oncology, Inc.
Citius Oncology logo
CountryUnited States
Founded2021
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
CEOLeonard Mazur

Contact Details

Address:
11 Commerce Drive, First Floor
Cranford, New Jersey 07016
United States
Phone908 967 6677
Websitecitiusonc.com

Stock Details

Ticker SymbolCTOR
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearOctober - September
Reporting CurrencyUSD
CIK Code1851484
CUSIP Number17331Y109
ISIN NumberUS17331Y1091
Employer ID99-4362660
SIC Code2834

Key Executives

NamePosition
Leonard L. MazurChief Executive Officer, President and Executive Chairman
Myron Z. HolubiakSecretary and Executive Vice Chairman
Dr. Myron S. Czuczman M.D.Executive Vice President and Chief Medical Officer
Jaime BartushakChief Financial Officer and Treasurer

Latest SEC Filings

DateTypeTitle
Aug 26, 2026ARSFiling
Aug 26, 2026DEF 14AOther definitive proxy statements
Aug 14, 2026424B3Prospectus
Aug 14, 202610-QQuarterly Report
Aug 14, 20268-KCurrent Report
Aug 14, 2026SCHEDULE 13G/AFiling
Aug 12, 20268-KCurrent Report
Aug 5, 2026424B3Prospectus
Aug 5, 20268-KCurrent Report
Jun 5, 2026EFFECTNotice of Effectiveness
View All SEC Filings